BCL2 and neoplasm: Similarly, in tumor types driven by BCL-2 transcription, PNT2258 should demonstrate good single-agent activity (compare WSU-DLCL2 with Daudi-Burkitt’s), but should potentiate the combination drug in tumor types with high BCL-2 expression if BCL-2 resistance is implicated in disease resistance (e.g., Daudi, PC-3, and A375).